Gencare-arthritis Pain Relief

The dosage of Diclofenac must be individualized to the lowest effective dose for the shortest possible duration to minimize the risk of cardiovascular and gastrointestinal adverse events. Healthcare providers typically follow these general guidelines for adults:

• Osteoarthritis: The standard dose is often 100 mg to 150 mg per day, divided into two or three doses (e.g., 50 mg twice or three times daily). If using extended-release tablets, 100 mg once daily is common.
• Rheumatoid Arthritis: The typical dosage ranges from 150 mg to 200 mg per day, divided into multiple doses (e.g., 50 mg three or four times daily).
• Ankylosing Spondylitis: The recommended dose is 100 mg to 125 mg per day, usually administered as 25 mg four times daily, with an extra 25 mg at bedtime if necessary.
• Acute Pain and Dysmenorrhea: Healthcare providers often prescribe 50 mg of Diclofenac Potassium three times daily. In some cases, an initial loading dose of 100 mg followed by 50 mg doses may be recommended.
• Migraine: For the treatment of acute migraine, a single 50 mg dose of Diclofenac Potassium for oral solution (powder packet) is the standard FDA-approved regimen.

Diclofenac is generally not recommended for use in children for general pain. However, some formulations are specifically approved for the treatment of Juvenile Rheumatoid Arthritis (JRA). For children aged 2 to 16 years with JRA, the typical dosage is 2 mg/kg to 3 mg/kg of body weight per day, divided into two or three doses. Safety and efficacy for other conditions in pediatric patients have not been established. Never give Diclofenac to a child or adolescent unless specifically directed by a pediatrician, as NSAIDs can occasionally be associated with serious risks in younger populations.

Renal Impairment

Diclofenac is not recommended for patients with advanced renal (kidney) disease. In patients with mild to moderate renal impairment, healthcare providers will monitor kidney function closely (serum creatinine and GFR). If kidney function declines during treatment, the medication may need to be discontinued.

Hepatic Impairment

Patients with mild hepatic (liver) impairment typically do not require an initial dose adjustment, but they must be monitored for signs of hepatotoxicity. Diclofenac should be used with extreme caution in patients with severe hepatic impairment, and lower doses are usually warranted.

Elderly Patients

Patients over the age of 65 are at a significantly higher risk for serious side effects, particularly gastrointestinal bleeding and kidney dysfunction. Clinical guidelines suggest starting at the lowest possible dose and monitoring these patients frequently for any signs of adverse reactions.

To ensure the medication works effectively and safely, follow these specific instructions:

• Administration: Swallow oral tablets whole. Do not crush, chew, or break enteric-coated or extended-release tablets, as this destroys the protective coating and increases the risk of stomach irritation.
• Food: You may take Diclofenac with food or milk to reduce stomach upset. However, taking it with food may slightly delay the onset of pain relief. For acute pain, taking it on an empty stomach may provide faster results, but this should be discussed with your doctor if you have a sensitive stomach.
• Hydration: Drink a full glass of water (8 ounces) with each dose to help the medication pass smoothly into the digestive system and support kidney function.
• Positioning: Avoid lying down for at least 10 to 15 minutes after taking the medication to prevent esophageal irritation.
• Storage: Store the medication at room temperature (68°F to 77°F), away from moisture, heat, and direct sunlight. Keep the container tightly closed.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to make up for a missed one, as this significantly increases the risk of gastrointestinal toxicity.

Symptoms of a Diclofenac overdose may include severe epigastric pain (pain in the upper abdomen), nausea, vomiting, drowsiness, lethargy, and in severe cases, gastrointestinal bleeding, hypertension (high blood pressure), acute renal failure, or coma. If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. Emergency management typically involves gastric lavage (stomach pumping) and the administration of activated charcoal if the overdose occurred recently.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, especially if you are using it for a chronic inflammatory condition.

Like all NSAIDs, Diclofenac is most frequently associated with gastrointestinal (GI) issues. More than 10% of patients may experience:

• Dyspepsia (Indigestion): A feeling of fullness, bloating, or burning in the upper abdomen.
• Nausea and Vomiting: General stomach upset that usually occurs shortly after taking the medication.
• Abdominal Pain: Cramping or discomfort in the stomach region.
• Diarrhea or Constipation: Changes in bowel habits are common as the drug affects prostaglandin levels in the gut.
• Headache: Mild to moderate head pain may occur as the body adjusts to the medication.
• Dizziness: A sensation of lightheadedness or spinning (vertigo).

These effects are often transient and may diminish as your body acclimates to the drug. Taking the medication with food can often mitigate the GI-related symptoms.

Between 1% and 10% of patients may experience:

• Fluid Retention (Edema): Swelling in the ankles, feet, or hands due to the drug's effect on sodium excretion in the kidneys.
• Tinnitus: A ringing or buzzing sound in the ears.
• Pruritus (Itching): Mild skin irritation or the development of a rash.
• Elevated Liver Enzymes: Borderline elevations of liver function tests (ALT/AST) occur in about 15% of patients taking Diclofenac.
• Flatulence: Increased gas and bloating.

While rare, these effects require careful monitoring:

• Photosensitivity: Increased sensitivity of the skin to sunlight, leading to easier sunburns.
• Insomnia: Difficulty falling or staying asleep.
• Paresthesia: Tingling or 'pins and needles' sensations in the extremities.
• Visual Disturbances: Blurred vision or changes in color perception.

> Warning: Stop taking Diclofenac and call your doctor immediately if you experience any of these symptoms. These may indicate life-threatening complications.

• Gastrointestinal Bleeding: Symptoms include black, tarry, or bloody stools (melena), or vomiting blood that looks like coffee grounds (hematemesis).
• Cardiovascular Events: Chest pain, shortness of breath, sudden weakness on one side of the body, slurred speech, or swelling of the face or throat (signs of heart attack or stroke).
• Hepatotoxicity (Liver Damage): Yellowing of the skin or eyes (jaundice), dark urine, severe fatigue, or pain in the upper right quadrant of the abdomen.
• Nephrotoxicity (Kidney Damage): Significant change in the amount of urine produced, painful urination, or blood in the urine.
• Severe Skin Reactions: Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN), characterized by a painful red or purplish rash that spreads and causes blistering and peeling.
• Anaphylaxis: A severe allergic reaction involving hives, difficulty breathing, and a drop in blood pressure.

Prolonged use of Diclofenac, particularly at high doses, increases the cumulative risk of several conditions:

• Chronic Kidney Disease: Continuous inhibition of renal prostaglandins can lead to interstitial nephritis and papillary necrosis.
• Hypertension: NSAIDs can cause a steady increase in blood pressure, which may require the initiation of antihypertensive therapy.
• Anemia: Long-term use can lead to chronic, low-level GI blood loss, resulting in iron-deficiency anemia.
• Gastrointestinal Ulcers: The risk of developing a perforated ulcer increases the longer the drug is used, especially in the elderly.

The FDA has issued a Black Box Warning for Diclofenac, the highest level of alert, regarding two major risks:

1. 1Cardiovascular Risk: NSAIDs, including Diclofenac, cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Diclofenac is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
2. 2Gastrointestinal Risk: NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.

Report any unusual symptoms to your healthcare provider immediately to ensure your treatment remains safe.

Diclofenac is a powerful medication that requires careful oversight by a healthcare professional. It is not a 'simple' pain reliever and carries significant systemic risks that must be balanced against its benefits. Patients with a history of heart disease, high blood pressure, or stomach ulcers must exercise extreme caution. It is vital to use the lowest effective dose for the shortest time possible to manage symptoms. Avoid taking multiple NSAIDs (such as ibuprofen, naproxen, or aspirin) simultaneously, as this dramatically increases the risk of toxicity without providing additional therapeutic benefit.

Cardiovascular Thrombotic Events: Clinical trials of several COX-2 selective and non-selective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 selective and non-selective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with Diclofenac, the lowest effective dose should be used for the shortest duration possible.

Gastrointestinal Bleeding, Ulceration, and Perforation: NSAIDs, including Diclofenac, cause an increased risk of serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These events can occur at any time during use and without warning symptoms. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic.

• Allergic Reactions / Anaphylaxis: Diclofenac can cause severe allergic reactions, especially in patients with the 'aspirin triad' (asthma, nasal polyps, and aspirin sensitivity). If you experience hives, swelling of the face, or difficulty breathing, seek emergency help.
• Hepatotoxicity: Rare but severe hepatic reactions, including liver necrosis, jaundice, and fulminant hepatitis, have been reported. Healthcare providers will typically perform baseline and periodic liver function tests (LFTs) if you are on long-term therapy.
• Hypertension: Diclofenac can lead to the onset of new hypertension or worsening of pre-existing high blood pressure. Blood pressure should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
• Heart Failure and Edema: Because NSAIDs can cause fluid retention and edema, Diclofenac should be used with caution in patients with fluid retention or heart failure.
• Hematological Effects: Diclofenac can inhibit platelet aggregation and may prolong bleeding time. Unlike aspirin, its effect on platelet function is reversible and of shorter duration.

If you are prescribed Diclofenac for a chronic condition, your healthcare provider will likely require regular monitoring, including:

• Complete Blood Count (CBC): To check for signs of anemia or infection.
• Liver Function Tests (ALT, AST, Bilirubin): Usually performed within 4 to 8 weeks of starting treatment and periodically thereafter.
• Renal Function (Creatinine, BUN, GFR): To ensure the kidneys are effectively clearing the medication and are not being damaged.
• Blood Pressure: Regular check-ups to ensure the drug is not causing hypertension.

Diclofenac can cause dizziness, drowsiness, or visual disturbances in some patients. If you experience these side effects, you should avoid driving, operating heavy machinery, or performing tasks that require mental alertness until you know how the medication affects you.

Consumption of alcohol while taking Diclofenac significantly increases the risk of gastrointestinal bleeding and stomach ulcers. It is generally advised to avoid or strictly limit alcohol intake during treatment. Even moderate alcohol consumption can irritate the stomach lining, which is already sensitized by the NSAID.

While Diclofenac does not have a formal 'withdrawal syndrome,' stopping the medication suddenly if you have been taking it for chronic inflammation may result in a rapid return of pain and stiffness. If you need to stop the medication, discuss a management plan with your doctor. There is no need for tapering for the purpose of preventing physiological withdrawal, but a gradual transition to another therapy may be clinically appropriate.

> Important: Discuss all your medical conditions, especially any history of heart, liver, or kidney disease, with your healthcare provider before starting Diclofenac.

Certain medications should never be combined with Diclofenac due to the risk of severe, life-threatening interactions:

• Ketorolac: Combining Diclofenac with other systemic NSAIDs like ketorolac exponentially increases the risk of gastrointestinal perforation and acute renal failure.
• Cidofovir: This antiviral medication is highly nephrotoxic; using it with Diclofenac can lead to permanent kidney damage.
• Aspirin (High Dose): While low-dose aspirin for heart protection is sometimes managed, high-dose aspirin should be avoided as it displaces Diclofenac from its protein-binding sites, increasing toxicity without increasing efficacy.

• Anticoagulants (Warfarin, Heparin, Apixaban): Diclofenac interferes with platelet function and can irritate the stomach lining. When combined with blood thinners, the risk of a major, potentially fatal gastrointestinal or systemic bleed is significantly elevated.
• Lithium: Diclofenac reduces the renal clearance of lithium, leading to increased lithium plasma levels and potential lithium toxicity (symptoms include tremors, confusion, and ataxia).
• Methotrexate: NSAIDs can inhibit the renal tubular secretion of methotrexate, leading to toxic levels of the drug in the blood, which can cause severe bone marrow suppression and mucosal sloughing.
• Cyclosporine and Tacrolimus: These immunosuppressants are nephrotoxic. Diclofenac increases the risk of kidney damage when used concurrently by affecting renal prostaglandins.

• ACE Inhibitors and ARBs (e.g., Lisinopril, Losartan): Diclofenac may reduce the blood-pressure-lowering effects of these drugs. Furthermore, the combination in elderly or dehydrated patients can lead to acute kidney failure.
• Diuretics (e.g., Furosemide, HCTZ): Diclofenac can reduce the natriuretic (sodium-removing) effect of diuretics, leading to fluid retention and decreased efficacy in treating heart failure or hypertension.
• SSRIs (e.g., Fluoxetine, Sertraline): Selective Serotonin Reuptake Inhibitors increase the risk of upper gastrointestinal bleeding when taken with NSAIDs.
• Digoxin: Diclofenac may increase serum digoxin concentrations and prolong its half-life.

• High-Fat Meals: Taking Diclofenac with a high-fat meal can delay the time to peak plasma concentration (Tmax) by several hours, though it does not reduce the total amount of drug absorbed. This is relevant if you need immediate pain relief.
• Alcohol: As noted previously, alcohol increases the risk of gastric mucosal damage and bleeding.

• Ginkgo Biloba, Garlic, Ginger, and Ginseng: These supplements have mild anti-platelet properties. Combining them with Diclofenac may further increase the risk of bruising and bleeding.
• St. John's Wort: May induce CYP2C9 enzymes, potentially leading to faster metabolism and reduced efficacy of Diclofenac.

Diclofenac does not typically interfere with common laboratory tests, but it can cause false-positive results in some urine drug screens for certain substances (though this is rare). It will affect tests for fecal occult blood (may cause a positive result due to minor GI bleeding).

For each major interaction, the management strategy usually involves either avoiding the combination, adjusting the dose of the interacting drug, or performing more frequent laboratory monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous interactions.

Diclofenac must NEVER be used in the following circumstances:

• Hypersensitivity: If you have a known allergy to Diclofenac or any of the inactive ingredients in the formulation.
• Aspirin-Sensitive Asthma: Patients who have experienced asthma, urticaria (hives), or allergic-type reactions after taking aspirin or other NSAIDs. This is due to the risk of severe, potentially fatal anaphylactic-like reactions.
• CABG Surgery: Diclofenac is strictly contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery, as it significantly increases the risk of myocardial infarction and stroke.
• Active Peptic Ulcer or GI Bleed: Use in patients with active bleeding or ulceration can lead to fatal perforation.
• Severe Heart Failure: Due to the risk of fluid retention and worsening cardiac strain.
• Third Trimester of Pregnancy: Use after 30 weeks of gestation is contraindicated due to the risk of premature closure of the ductus arteriosus in the fetus.

These conditions require a careful risk-benefit analysis by a healthcare provider:

• Moderate Renal Impairment: Requires close monitoring; the drug may exacerbate kidney dysfunction.
• Coagulation Disorders: Patients with hemophilia or other bleeding disorders are at higher risk of complications.
• History of GI Disease: Including Crohn's disease or ulcerative colitis, which may be exacerbated by NSAID use.
• Porphyria: Diclofenac may trigger an attack in patients with hepatic porphyria.

There is a high degree of cross-sensitivity between Diclofenac and other NSAIDs. If you have had a severe reaction (like swelling or difficulty breathing) to ibuprofen, naproxen, celecoxib, or indomethacin, you are highly likely to react to Diclofenac as well. Always inform your healthcare provider of any previous drug allergies before starting a new medication.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Diclofenac to ensure it is safe for you.

Diclofenac use during pregnancy is complex and depends on the gestational age.

• First and Second Trimester: Diclofenac is generally classified as Category C. Some studies suggest an increased risk of miscarriage and congenital malformations (like heart defects) when NSAIDs are used in early pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.
• Third Trimester (30 weeks and beyond): Diclofenac is Category D and is strictly contraindicated. NSAIDs can cause premature closure of the fetal ductus arteriosus (a vital blood vessel in the fetal heart), leading to pulmonary hypertension in the newborn. It may also inhibit uterine contractions, delaying or prolonging labor.
• Oligohydramnios: Use of NSAIDs around 20 weeks of pregnancy or later may cause fetal kidney dysfunction leading to oligohydramnios (low amniotic fluid) and, in some cases, neonatal renal impairment.

Diclofenac is excreted into human breast milk in very small amounts. In limited studies, a dose of 150 mg daily produced milk levels that were considered too low to be harmful to a nursing infant. However, because of the potential for serious adverse reactions in nursing infants from Diclofenac, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Diclofenac is not approved for general use in children under 18 for acute pain. Its use is limited to Juvenile Rheumatoid Arthritis (JRA) in specific formulations for children aged 2 and older. Pediatric patients may be more susceptible to certain side effects, and growth monitoring is sometimes recommended during long-term therapy for JRA.

Patients aged 65 and older are at the highest risk for Diclofenac-related complications. Age-related declines in renal and hepatic function mean the drug may clear more slowly from the body. The risk of fatal GI bleeding is significantly higher in this population. Clinical guidelines recommend starting at the lowest end of the dosing range and monitoring for signs of occult GI bleeding (such as anemia or dark stools) and kidney stress.

Diclofenac is not recommended in patients with advanced renal disease. For those with mild to moderate impairment, no specific starting dose adjustment is usually required, but the glomerular filtration rate (GFR) must be monitored. Prostaglandins help maintain renal perfusion; by blocking them, Diclofenac can cause a sudden drop in kidney function, particularly in patients who are dehydrated or taking diuretics.

Since Diclofenac is primarily metabolized by the liver, patients with hepatic impairment (Child-Pugh Class A or B) should be monitored closely for worsening liver function. In patients with severe hepatic impairment (Child-Pugh Class C), the use of Diclofenac is generally avoided due to the increased risk of toxicity and bleeding.

> Important: Special populations require individualized medical assessment and frequent monitoring to ensure the safest possible outcomes.

Diclofenac is a potent inhibitor of cyclooxygenase (COX), the enzyme responsible for the synthesis of prostaglandins and thromboxanes from arachidonic acid. It is a non-selective NSAID, meaning it inhibits both the COX-1 and COX-2 isoforms. COX-1 is involved in 'housekeeping' functions like gastric mucosal protection and platelet aggregation, while COX-2 is induced during inflammation. By reducing the production of Prostaglandin E2 (PGE2), Diclofenac effectively raises the pain threshold and reduces the vasodilation and edema associated with the inflammatory response. Additionally, Diclofenac may reduce intracellular concentrations of free arachidonic acid in leukocytes, potentially by altering fatty acid transport.

The pain-relieving effects of Diclofenac typically begin within 30 to 60 minutes for immediate-release formulations, while the full anti-inflammatory effects for conditions like arthritis may take up to two weeks of consistent dosing to reach their peak. There is a clear dose-response relationship; however, increasing the dose beyond the recommended maximums does not significantly increase efficacy but does dramatically increase the risk of adverse events. Tolerance to the analgesic effects does not typically develop, but the risk of systemic toxicity increases over time.

| Parameter | Value |

|---|---|

| Bioavailability | ~50% (due to first-pass metabolism) |

| Protein Binding | >99.7% (primarily to albumin) |

| Half-life | 1.2 to 2.0 hours (plasma) |

| Tmax | 1-2 hours (Potassium); 2-3 hours (Sodium EC) |

| Metabolism | Hepatic (CYP2C9 hydroxylation) |

| Excretion | Renal 65%, Fecal 35% |

• Molecular Formula: C14H11Cl2NO2 (as Diclofenac acid)
• Molecular Weight: 296.15 g/mol
• Solubility: Sparingly soluble in water at low pH; soluble in ethanol and methanol. The sodium and potassium salts increase water solubility for pharmaceutical formulations.
• Structure: It is a derivative of benzeneacetic acid, containing two chlorine atoms and an amino group, which contributes to its high potency and lipophilicity.

Diclofenac is classified as a nonsteroidal anti-inflammatory drug (NSAID) and specifically falls under the acetic acid derivative group. It is therapeutically related to medications such as indomethacin, etodolac, and ketorolac. Within the broader category of analgesics, it is distinct from opioids as it does not bind to mu-opioid receptors and does not carry a risk of physical dependence or respiratory depression.